Aimmune Expects ‘Robust’ Demand For Peanut Allergy Treatment Palforzia, Though Slow Launch
The COVID-19 Pandemic Is Expected To Affect The Launch
Aimmune CEO Jayson Dallas talked to Scrip about the company's field team, allergists' and payers' responses to the first food-derived medicine, and why Viaskin Peanut patch is not a competitive threat.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Moderna gets green light to proceed to Phase II trial of mRNA vaccine, with its eagerly-awaited Phase I results expected shortly.
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.